Lyme disease vaccine - Baxter Healthcare

Drug Profile

Lyme disease vaccine - Baxter Healthcare

Alternative Names: mv rOspA LB vaccine

Latest Information Update: 15 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator State University of New York
  • Developer Baxter Healthcare Corporation
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Lyme disease

Most Recent Events

  • 15 Sep 2015 No recent reports on development identified - Phase-I/II for Lyme disease (Prevention, In volunteers) in Austria and Germany (IM)
  • 06 Aug 2014 Lyme disease vaccine - Baxter Healthcare Corporation is available for licensing or divestiture as of 30 July 2014. http://www.baxter.com/
  • 01 Feb 2014 Baxter Healthcare Corporation completes a phase I/II trial in Lyme disease (in volunteers, prevention) in Austria and Germany (NCT01504347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top